Bilateral Non-Arteritic Anterior Ischemic Optic Neuropathy Following Weight Loss from Semaglutide (Ozempic): A Case Report

Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) is generally triggered by local features such as optic disc at risk and systemic factors. Semaglutide is a glucagon-like peptide-1 receptor agonist approved for treating hypertension, diabetes, obesity, and dyslipidemia. The case reports occurrence of sequential NAION in a patient with weight loss on Semaglutide. Case Presentation A 73-year-old man with a history of type 2 diabetes, obesity, and hypertension experienced bilateral NA-AION after significant weight reduction and associated postural hypotension on semaglutide. Conclusion This case report highlights the importance of considering NA-AION as a possible adverse effect of semaglutide use, particularly in patients with preexisting risk factors for optic nerve ischaemia.